Fig 1: Validation of gene expression in CRC cell lines. (A-F) RT-qPCR analysis of mRNA levels of PLCE1, PTGS1, AMT, ST8SIA1, GBA2, and ST3GAL5 in CRC cell lines and the normal human colon epithelial cell line NCM460. (G) Western blotting for evaluating protein levels of GBA2 and ST3GAL5 in different cell lines. CRC, colorectal cancer; RT-qPCR, real-time quantitative polymerase chain reaction. **P < .01.
Fig 2: Overexpression efficiency of GBA2 or ST3GAL5 in CRC cells. RT-qPCR (A) and western blotting (B) for detecting GBA2 mRNA and protein expression in CRC cells with/without GBA2-OE transfection. RT-qPCR (C) and western blotting (D) for detecting ST3GAL5 mRNA and protein expression in CRC cells with/without ST3GAL5-OE transfection. CRC, colorectal cancer; mRNA, messenger ribonucleic acid; RT-qPCR, real-time quantitative polymerase chain reaction. **P < .01.
Fig 3: Upregulating GBA2 or ST3GAL5 impacts CRC cell viability and apoptosis. CCK-8 assay showing CRC cell viability with/without upregulation of (A) GBA2 or (B) ST3GAL5. (C-E) Flow cytometry for detecting apoptotic CRC cells in different treatment groups. CRC, colorectal cancer. **P < .01.
Fig 4: Overexpressing GBA2 or ST3GAL5 affects CRC cell motility. Transwell assays for detecting CRC cell migration (A) and invasion (B) with/without GBA2 upregulation. Transwell assays for detecting CRC cell migration (C) and invasion (D) with/without ST3GAL5 upregulation. CRC, colorectal cancer. **P < .01.
Supplier Page from Abcam for Anti-GBA2 antibody